Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis.
Yusaku HashimotoSawako KatoMakoto Kuro-OYutaka MiuraYuya ItanoMasahiko AndoYachiyo KuwatsukaShoichi MaruyamaPublished in: Nephrology (Carlton, Vic.) (2022)
Etelcalcetide may be useful through suppression of FGF23 levels among haemodialysis patients with SHPT. When correcting hypocalcaemia, loading oral calcium preparations could be more advantageous than active vitamin D for the suppression of both FGF23 and CPPs.